Neural cell replacement therapy - Ophiuchus Technologies

Drug Profile

Neural cell replacement therapy - Ophiuchus Technologies

Alternative Names: Autologous neural stem cell therapy - Ophiuchus Technologies; Autologous neural stem cells - Ophiuchus Technologies; Directly reprogrammed neural stem cells - Ophiuchus Technologies; DrSC™ Neural

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ophiuchus Technologies
  • Developer Federal Medical and Biological Agency of Russia; Ophiuchus Technologies
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Preclinical Brain injuries

Most Recent Events

  • 06 Apr 2017 Phase-I/II development for Spinal cord injuries is ongoing in Russia (Intrathecal), (Intraspinal)
  • 01 Jun 2014 Phase-I/II clinical trials in Spinal cord injuries in Russia (Intraspinal, Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top